SBIR/STTR Research Award

Overproduction of polyketide antimicrobials

Award identifier b615b3b1efce14b5c944038828ee45a3a1fa13fa90cb78c122363375cbd67051Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$750,000

Program and phase

SBIR · Phase II

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Kosan Biosciences, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Polyketides are a diverse class of natural products with an established history of clinical utility (e.g. erythromycin, FK506, Iovastatin). Conventional strain improvement processes are necessary to make therapeutically important polyketides commercially attractive but are time consuming and tedious. The long term goals of this work are to develop generic approaches to polyketide overproduction and then apply these approaches to the generation of novel polyketide antimicrobials. In this proposal, we are targeting the production of novel erythromycin analogs for lead generation and preclinical development of ketolide and motilide therapeutics. Ketolides are a new class of potent antibiotics with activity against erythromycin sensitive organisms. Motilides are motilin receptor agonists being developed for treatment of gastric pariesis, gastric reflux disease and other uses. The specific aims of this proposal are: i.) to use an erythromycin overproducing system developed in Phase I to express several genetically modified erythromycin PKS genes and produce fully mature erythromycin analogs needed for early and late stage testing, and ii.) to adapt the system to one that will efficiently incorporate synthetic diketide-SNAC precursors into the polyketide product and produce erythromycin analogs by precursor-directed biosynthesis. As specific aim iii), we plan to initiate development of a second generation generic overproduction host in the widely used actinomycete host Streptomyces coelicolor. These aims will facilitate the advancement of ketolide and motilide compounds that are in late stage preclinical development, potentially generate new leads for development, and expand the diversity of structures that can be achieved through the genetic manipulation of polyketide synthases in microbiological systems. Furthermore, the establishment of well-defined overproduction hosts will facilitate analyzing the molecular and physiological basis of overproduction.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.